25 final copy
10 final
25 final copy
10 final

Empacoza TRIO 10/5/1000 mg &25/5/1000 mg

Pharmaceutical

تفاصيل المنتج:

منشور

Composition:

EMPACOZA TRIO tablets for oral use contain: empagliflozin, linagliptin, and metformin HCl.

Each extended release film-coated tablet of EMPACOZA TRIO consists of an extended-release metformin hydrochloride core tablet that is coated with the immediate-release drug substances: empagliflozin and linagliptin.

 

EMPACOZA TRIO tablets for oral administration are available in four strengths containing:

·         10 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl

·         25 mg empagliflozin (micronized), 5 mg linagliptin (micronized) and 1,000 mg metformin HCl

 

INDICATIONS AND USAGE:

 

EMPACOZA TRIOis a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease

 

 

HOW SUPPLIED/STORAGE AND HANDLING

 

EMPACOZA TRIO tablets are available as follows:

 

 

Tablet Strength


Package Size


10 mg Empagliflozin (micronized)

5 mg Linagliptin (micronized)

1,000 mg Metformin HCl Extended release


 

Carton box containing (AL/AL) strips each strip of 10 extended release film coated tablets and inner leaflet


25 mg Empagliflozin (micronized)

5 mg Linagliptin (micronized)

1,000 mg Metformin HCl Extended release

Carton box containing (AL/AL) strips each strip of 10 extended release film coated tablets and inner leaflet